Q2 2026 Mineralys Therapeutics, Inc. Earnings Call Transcript
Key Points
- Mineralys Therapeutics Inc (MLYS) reported positive clinical data, including a 52% placebo-adjusted reduction in urine albumin-to-creatinine ratio in CKD patients and significant reductions in heart failure biomarkers, supporting lorundrostat's potential in related comorbidities.
- The company strengthened its financial position with a $150 million equity offering and a $500 million committed senior secured term loan facility, providing capital to fund operations and the commercial launch into 2028.
- Mineralys Therapeutics Inc (MLYS) repurchased future royalty payments due to Tanabe Pharma for $200 million upfront and up to $100 million in milestones, enhancing long-term value of lorundrostat.
- Commercial launch readiness is progressing well, with payer engagement covering the vast majority of US covered lives and a sales force expected to be staffed ahead of the December PDUFA date.
- The company's clinical profile, including data from the Advance-HTN trial, is resonating with KOLs and physicians, with market research showing a 2-to-1 preference for lorundrostat's profile over baxdrostat.
- Mineralys Therapeutics Inc (MLYS) reported a significant net loss of $241.1 million for Q2 2026, driven by the $200 million upfront payment to Tanabe and increased R&D and G&A expenses.
- The company faces competition from AstraZeneca's baxdrostat, which has already launched, and there is uncertainty regarding payer coverage and pricing strategies in a competitive market.
- Label and post-marketing discussions with the FDA have not yet begun, with expectations for October/November, creating uncertainty about final label language and potential differentiation.
- The company has not yet locked in pricing for lorundrostat, and there is a risk of a downward pricing spiral if not managed carefully, as noted by the Chief Commercial Officer.
- Medicare Part D formulary cycle timing may result in a progressive increase in coverage through 2027, with commercial outpacing Medicare, potentially limiting early adoption in the Medicare population.
Welcome to the Mineralys Therapeutics second quarter 2026 conference call. Reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Dan Ferry of LifeSci Advisors. Please go ahead, sir.
Thank you. I would like to welcome everyone joining us today for our second quarter 2026 conference call. This afternoon, after the close of market trading, we issued a press release providing our second quarter 2026 financial results and business updates.
A replay of todayâs call will be available on the investors section of our website approximately one hour after its completion. After our prepared remarks, we will open the call for Q&A. Before we begin, I would like to remind everyone that this conference call and webcast will contain forward-looking statements about the company. Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the companyâs business. These forward
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
